The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

April 30, 2026

Conditions
Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma
Interventions
DRUG

NAB-Paclitaxel plus Cisplatin

NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.

DRUG

Cisplatin plus Epirubicin plus Cyclophosphamide

Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.

Trial Locations (1)

200032

Yian Zhang, Shanghai

All Listed Sponsors
lead

Peng Liu

OTHER